173 related articles for article (PubMed ID: 38142939)
1. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial.
Audinot B; Drubay D; Gaspar N; Mohr A; Cordero C; Marec-Bérard P; Lervat C; Piperno-Neumann S; Jimenez M; Mansuy L; Castex MP; Revon-Riviere G; Marie-Cardine A; Berger C; Piguet C; Massau K; Job B; Moquin-Beaudry G; Le Deley MC; Tabone MD; Berlanga P; Brugières L; Crompton BD; Marchais A; Abbou S
Ann Oncol; 2024 Jun; 35(6):559-568. PubMed ID: 38142939
[TBL] [Abstract][Full Text] [Related]
2. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.
Shulman DS; Klega K; Imamovic-Tuco A; Clapp A; Nag A; Thorner AR; Van Allen E; Ha G; Lessnick SL; Gorlick R; Janeway KA; Leavey PJ; Mascarenhas L; London WB; Vo KT; Stegmaier K; Hall D; Krailo MD; Barkauskas DA; DuBois SG; Crompton BD
Br J Cancer; 2018 Aug; 119(5):615-621. PubMed ID: 30131550
[TBL] [Abstract][Full Text] [Related]
3. Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma.
Krumbholz M; Eiblwieser J; Ranft A; Zierk J; Schmidkonz C; Stütz AM; Peneder P; Tomazou EM; Agaimy A; Bäuerle T; Hartmann W; Dirksen U; Metzler M
Clin Cancer Res; 2021 Nov; 27(21):5922-5930. PubMed ID: 34426444
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.
Yang Q; Chen T; Yao Z; Zhang X
World J Surg Oncol; 2020 Jan; 18(1):24. PubMed ID: 32000789
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer.
Nørgaard M; Bjerre MT; Fredsøe J; Vang S; Jensen JB; De Laere B; Grönberg H; Borre M; Lindberg J; Sørensen KD
Clin Chem; 2023 Apr; 69(4):386-398. PubMed ID: 36762756
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience.
Bastard P; Cozic N; Brion R; Gaspar N; Piperno-Neumann S; Cordero C; Leculée-Thébaud E; Gomez-Mascard A; Rédini F; Marchais A; Ikonomova R; Cleirec M; Laurence V; Rigaud C; Abbas R; Verrecchia F; Brugières L; Minard-Colin V
Pediatr Blood Cancer; 2024 Jul; 71(7):e31029. PubMed ID: 38679845
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD; Brugières L; Piperno-Neumann S; Selva MA; Marec-Bérard P; Pacquement H; Lervat C; Corradini N; Gentet JC; Couderc R; Chevance A; Mahier-Ait Oukhatar C; Entz-Werle N; Blay JY; Le Deley MC
BMC Cancer; 2017 Jun; 17(1):419. PubMed ID: 28619014
[TBL] [Abstract][Full Text] [Related]
9. A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG.
Flores RJ; Kelly AJ; Li Y; Nakka M; Barkauskas DA; Krailo M; Wang LL; Perlaky L; Lau CC; Hicks MJ; Man TK
Cancer; 2017 Jan; 123(1):144-154. PubMed ID: 27529817
[TBL] [Abstract][Full Text] [Related]
10. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
Pietrasz D; Wang-Renault S; Taieb J; Dahan L; Postel M; Durand-Labrunie J; Le Malicot K; Mulot C; Rinaldi Y; Phelip JM; Doat S; Blons H; de Reynies A; Bachet JB; Taly V; Laurent-Puig P
Br J Cancer; 2022 Feb; 126(3):440-448. PubMed ID: 34811505
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma.
Ma B; Li M; Zhang L; Huang M; Lei JB; Fu GH; Liu CX; Lai QW; Chen QQ; Wang YL
Tumour Biol; 2016 Apr; 37(4):4445-55. PubMed ID: 26499949
[TBL] [Abstract][Full Text] [Related]
14. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
15. How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?
Tsoi KM; Lowe M; Tsuda Y; Lex JR; Fujiwara T; Almeer G; Gregory J; Stevenson J; Evans SE; Botchu R; Jeys LM
Clin Orthop Relat Res; 2021 Feb; 479(2):298-308. PubMed ID: 32956141
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
[TBL] [Abstract][Full Text] [Related]
17. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Molecular Analysis of Pathologic Fracture-associated Osteosarcoma: MicroRNA profile Is Different and Correlates with Prognosis.
Lozano Calderón SA; Garbutt C; Kim J; Lietz CE; Chen YL; Bernstein K; Chebib I; Nielsen GP; Deshpande V; Rubio R; Wang YE; Quackenbush J; Delaney T; Raskin K; Schwab J; Cote G; Spentzos D
Clin Orthop Relat Res; 2019 Sep; 477(9):2114-2126. PubMed ID: 31389890
[TBL] [Abstract][Full Text] [Related]
19. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
20. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
Sumanasuriya S; Seed G; Parr H; Christova R; Pope L; Bertan C; Bianchini D; Rescigno P; Figueiredo I; Goodall J; Fowler G; Flohr P; Mehra N; Neeb A; Rekowski J; Eisenberger M; Sartor O; Oudard S; Geffriaud-Ricouard C; Ozatilgan A; Chadjaa M; Macé S; Lord C; Baxter J; Pettitt S; Lambros M; Sharp A; Mateo J; Carreira S; Yuan W; de Bono JS
Eur Urol; 2021 Aug; 80(2):243-253. PubMed ID: 34103179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]